loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Gedatolisib

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Gedatolisib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Celcuity Plans Phase 3 Gedatolisib Trial Secures 62M Debt Financing
    Celcuity Plans Phase 3 Gedatolisib Trial Secures 62M Debt Financing

    30 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/30/2890595/0/en/Celcuity-Inc-Announces-Plan-to-Initiate-a-Phase-3-Clinical-Trial-for-Gedatolisib-as-First-Line-Treatment-for-HR-HER2-Advanced-Breast-Cancer-and-Secures-Approximately-62-Million-Deb.html

    GLOBENEWSWIRE
    30 May 2024
    Share Share
    Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
    Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results

    27 Mar 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/03/27/2853589/0/en/Celcuity-Inc-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Corporate-Update.html

    GLOBENEWSWIRE
    27 Mar 2024
    Share Share
    Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 of Gedatolisib
    Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 of Gedatolisib

    22 Feb 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/02/22/2834087/0/en/Celcuity-Announces-First-Patient-Dosed-in-Phase-1b-2-CELC-G-201-Clinical-Trial-of-Gedatolisib-for-the-Treatment-of-Metastatic-Castration-Resistant-Prostate-Cancer.html

    GLOBENEWSWIRE
    22 Feb 2024
    Share Share
    Celcuity Presents Data on Therapeutic Effects of Gedatolisib in Breast Cancer
    Celcuity Presents Data on Therapeutic Effects of Gedatolisib in Breast Cancer

    06 Dec 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/12/06/2791761/0/en/Celcuity-Presents-Preclinical-Data-on-Therapeutic-Effects-of-Gedatolisib-in-Breast-Cancer-Models-at-the-2023-San-Antonio-Breast-Cancer-Symposium.html

    GLOBENEWSWIRE
    06 Dec 2023
    Share Share
    Celcuity to Present Preclinical Data for Gedatolisib
    Celcuity to Present Preclinical Data for Gedatolisib

    01 Dec 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/12/01/2789413/0/en/Celcuity-to-Present-Preclinical-Data-for-Gedatolisib-at-the-2023-San-Antonio-Breast-Cancer-Symposium.html

    GLOBENEWSWIRE
    01 Dec 2023
    Share Share
    Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib
    Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib

    09 Dec 2022

    // ACCESSWIRE

    https://www.accesswire.com/731101/Celcuity-Presents-Updated-Results-of-Phase-1b-Study-of-Gedatolisib-in-Patients-with-Advanced-Breast-Cancer-at-the-2022-San-Antonio-Breast-Cancer-Symposium

    ACCESSWIRE
    09 Dec 2022
    Share Share